Puja Sapra is Vice President at the Oncology Research and Development Group. Dr. Sapra leads the research group responsible for preclinical development of targeted therapeutics including nanomedicines, bioconjugates and antibody drug conjugate. Her group has built novel sophisticated technologies to develop antibody drug conjugate molecules and has advanced several of these candidate molecules to clinical trials. Dr. Sapra received her PhD in Pharmacology from University of Alberta, Canada, her BS from All India Institute of Medical Sciences, and her MS in Pharmacology from UK. She is an author of >50 scientific publications, book chapters and co-inventor on several issued patents. Prior to joining Pfizer, Dr. Sapra led Pharmacology groups at Enzon Pharmaceuticals and Immunomedics Inc. and developed oncology-based drugs that are undergoing clinical evaluation. She has broad expertise in targeting strategies including immunotherapeutics, liposomal drug delivery system, nanoparticles, antisense oligonucleotide delivery and pegylation technologies.

 immunotherapeutics, liposomal drug delivery system, nanoparticles, antisense oligonucleotide delivery and pegylation technologies